Connect with us

Technology

New Report from Clarivate and Healthcare Executive Explores Mainland China’s Biopharma Revolution and Increasing Global Influence

Published

on

New report analyses Mainland China’s transformation into a global biopharma powerhouse, with key insights for international stakeholders

LONDON, Nov. 18, 2024 /CNW/ — Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership with Healthcare Executive, published by the China Pharmaceutical Enterprises Association, today announced the release of a new report, A Decade of Innovation, A Decade to Come.

Over the past decade, Mainland China’s biopharmaceutical sector has rapidly advanced to become a global leader in innovation, ranking among the top three for initial drug launches. Driven by reforms, increased investment, and progressive policies, the industry has reduced approval timelines, raised regulatory standards, and improved patient access to advanced therapies. Insights from the Institute for Scientific Information™ show that China’s Gross Expenditure on Research and Development has grown 3.5 times over the past decade, outpacing growth rates in the UK and the U.S.1 These developments, combined with an evolving healthcare reimbursement system, have enabled both domestic and multinational companies to bring new therapies to market, benefiting millions of patients.

Henry Levy, President, Life Sciences & Healthcare, Clarivate, said: “Mainland China’s ascent in the biopharma sector reflects the power of sustained investment and strategic reform. This report not only highlights the impressive achievements of the past decade but also underlines the far-reaching potential for Chinese biopharma companies to drive global medical innovation and enhance patient outcomes worldwide.”

Tan Yong, Vice President of China Pharmaceutical Enterprises Association and Publisher of Healthcare Executive, noted: “The pharmaceutical industry is poised for significant and transformative changes in the upcoming decade, driven by heightened competition. Rapid innovation and intense competition have reshaped market dynamics, leading to more focused and sustainable growth. The report offers the industry a glimpse of how Chinese pharmaceutical companies can prioritize innovation and international expansion in the next decade.”

Alice Zeng, Senior Solution Consultant, Life Sciences & Healthcare, Clarivate, added: “This report is an invaluable resource for global industry stakeholders. For pharma companies worldwide, it provides a timely understanding of Mainland China’s biopharma landscape, covering the opportunities for international collaboration and the potential for accelerated market entry.”

The report highlights Mainland China’s regulatory advancements, rapid drug launch growth, and expanding domestic R&D role. Key updates include the National Reimbursement Drug List (NRDL), where systematic price negotiations have cut costs by 50-60%, improving access to innovative drugs. Additionally, Mainland China’s share of global licensing and service deals has grown from 6.5% to nearly 9% since 2015, and the country now leads in publishing research and filing patents in key life sciences, underscoring its rising influence on the global industry.

Key insights in A Decade of Innovation, A Decade to Come, include:

Impactful policy reforms: How regulatory initiatives such as the Marketing Authorization Holder (MAH) system and priority review programs have streamlined approvals and bolstered R&D.Healthcare accessibility and innovation: An examination of Mainland China’s healthcare reforms, including the expansion of the NRDL and commercial health insurance, increasing access to cutting-edge therapies.Investment and R&D growth: Analysis of Mainland China’s record-breaking R&D investment, driving advancements in oncology, anti-infectives, and emerging therapeutic areas.Global Integration and market opportunities: Insights into the rise of Mainland China’s biopharma sector as a global player, including the increase in multinational collaborations and first-to-market launches.

With Mainland China’s share of first-time global drug launches growing, and as new therapeutic areas advance, A Decade of Innovation, A Decade to Come provides timely, in-depth insights for international investors, multinational pharmaceutical companies, and healthcare stakeholders who seek to understand Mainland China’s role in shaping the future of the biopharma landscape.

The A Decade of Innovation, A Decade to Come report draws on comprehensive data and tools trusted by the global life sciences community, including Cortellis Competitive Intelligence, Cortellis Regulatory Intelligence™, Disease Landscape & Forecast, Cortellis Deals Intelligence, Cortellis Clinical Trials Intelligence™, Cortellis Product Intelligence™, Real World Data and Analytics, Access and reimbursement payer studies, BioWorld™, Web of Science™ and Derwent Innovation™ among others. Compiled by Clarivate analysts using data gathered prior to August 31, 2024, this report reflects Clarivate’s commitment to supporting drug, device, and medical technology lifecycles. By combining patient journey data, therapeutic insights, and AI-driven analytics, Clarivate enables evidence-based decisions that advance human health.

To learn more about the Clarivate report, A Decade of Innovation, A Decade to Come, visit here.

About Healthcare Executive
With media as the outpost, conference as the platform, live video broadcasting as the tool, and expert pharmaceutical industry observers and recorders as the living force, Healthcare Executive (E药经理人) brings the top consensus of entrepreneurs, scientists, and investors in the pharmaceutical industry together on the one hand, and on the other hand gathers multi-dimensional and multi-level resources from the whole industry chain. We are dedicated to providing in-depth professional communication opportunities and influential solutions for the whole industry chain in their whole life cycle. In this regard, we make connections with client requirements upstream and downstream and make preparations for the overseas strategy in their international programs.

About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

Media Contact 
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
Clarivate
newsroom@clarivate.com

1 Source: Global Research Report: China’s research landscape, ISI, Clarivate

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-report-from-clarivate-and-healthcare-executive-explores-mainland-chinas-biopharma-revolution-and-increasing-global-influence-302307317.html

SOURCE Clarivate Plc

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Eficode receives Atlassian Partner of the Year 2026 for Software Solutions

Published

on

By

Eficode has been named Atlassian Partner of the Year 2026 for Software Solutions, recognizing performance in new business development, thought leadership, and delivering solutions that complement Atlassian’s offering.

HELSINKI, May 5, 2026 /PRNewswire/ — Atlassian announced today that Eficode has been awarded the Atlassian Partner of the Year 2026 for Software Solutions in recognition of their exemplary contributions and achievements throughout the calendar year 2025. This accolade acknowledges exceptional performance in new business development, thought leadership, and the delivery of products and services that effectively complement Atlassian’s offerings.

Eficode was among the select group of partners honored at the annual Atlassian Partner of the Year awards, in recognition of their sustained commitment and outstanding customer engagement.

“Our Partner of the Year winners represent the very best of our ecosystem—driving innovation, delivering cutting-edge solutions, and demonstrating an unwavering commitment to customer success. We are proud to celebrate their achievements and recognize the incredible impact they’ve made in helping customers unlock their full potential with Atlassian,” said Bill Hustad, Head of Channel and GTM Ecosystems at Atlassian.

“This recognition reflects the trust our customers place in us and the dedication of our teams every day. We focus on helping organizations use AI in the software development lifecycle and build effective software tooling that supports real business outcomes. It’s rewarding to see the impact this has on our clients’ success, and we’re excited to keep building on that with Atlassian,” said Henri Hämäläinen, Chief Product Officer and Co-CEO of Eficode.

Eficode brings deep experience in AI-driven software development and building effective SDLC tooling that helps teams work smarter. They have supported organizations such as Air France–KLM, Supercell, and The Very Group in saving costs, future-proofing their environment for innovation, and building more efficient software processes and better customer experiences. Learn more about Eficode’s work with Atlassian solutions.

Media contacts
Henri Hämäläinen, CPO, Co-CEO at Eficode, henri.hamalainen@eficode.com, +358 50 487 3291
Simon Wood, CRO, Co-CEO at Eficode, simon.wood@eficode.com, +44 7920 002769

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/eficode-oy/r/eficode-receives-atlassian-partner-of-the-year-2026-for-software-solutions,c4343859

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/eficode-receives-atlassian-partner-of-the-year-2026-for-software-solutions-302762305.html

Continue Reading

Technology

Bizcap launches Line of Credit in Europe to meet growing SME demand

Published

on

By

MUNICH, May 5, 2026 /PRNewswire/ — Small and medium-sized enterprises (SMEs) in Europe can now access up to €500,000 in funding thanks to a flexible, fast-turnaround line of credit offered by Bizcap.

The Line of Credit is designed to help businesses manage cash flow, respond to seasonal pressures, and act on growth opportunities. The new facility offers set-up within two to three days, followed by ongoing access to funds as needed.

Bizcap’s Business Line of Credit gives SMEs a more adaptable funding solution than many traditional lending products, with flexible drawdowns and repayments aligned to business cash flow. Businesses only pay for the funds they use, and once the facility is in place, they can access capital as needed without having to reapply each time.

The launch comes as Bizcap builds on a strong start in Europe, following its launch into Luxembourg in July 2025, then expanding lending into Germany in October 2025, where it facilitated more than €4 million in funding in its first month of lending. Bizcap has described Germany as its most successful international expansion to date, underlining strong product-market fit and the effectiveness of its partnerships-led strategy in Europe.

“Europe has responded favourably to Bizcap’s fast, flexible and transparent approach to funding, and that’s exactly why this Line of Credit launch matters,” said Laura Schlag, Managing Partner for Bizcap Europe.

“Our early traction in Luxembourg and Germany showed us there is clear demand from SMEs for funding that moves at the speed of business. With our Line of Credit, businesses can access capital when they need it, use only what they need, and stay in control of their cash flow.

“For many SMEs, funding needs don’t arrive in one neat moment. They ebb and flow with stock purchases, supplier payments, payroll, tax obligations, and growth opportunities. This product is designed to meet that reality with flexibility, speed and clarity.”

Bizcap’s Line of Credit has already proven itself in other international markets, where the product has seen strong uptake from SMEs seeking reliable working capital and repeat access to funding. Its expansion into Europe reflects Bizcap’s broader strategy to bring practical, flexible business finance to underserved SME markets.

Albert Gahfi, Bizcap’s Global Co-CEO, said the launch of Line of Credit in Europe reflects both market demand and Bizcap’s confidence in the region’s long-term potential.

“We’ve seen in Luxembourg and Germany just how strongly SMEs and partners respond when funding is fast, transparent and built around real business needs,” he said.

“Launching our Line of Credit in Europe is a natural next step. It gives businesses an ongoing source of capital they can draw on as opportunities arise, without the friction of starting from scratch each time.

“Our model is built to move quickly, but it’s also built to understand businesses properly. We look beyond rigid scorecards and assess overall financial health, which means we can support a broader range of SMEs with practical, responsible funding solutions.”

This broader underwriting approach and Bizcap’s focus on overall business health are themes the company has highlighted in its European rollout.

Bizcap works closely with advisers, brokers and partners across its markets to help deliver funding solutions to a broader range of business clients. In Europe, that partnership-led approach has already played a major role in its early growth, where Bizcap says trust, credibility and strong broker relationships were key to its first-month results.

Bizcap is offering select advisers access to bring this solution to their clients. Interested advisers can email partners@bizcap.eu or become a partner via their website.

View original content:https://www.prnewswire.co.uk/news-releases/bizcap-launches-line-of-credit-in-europe-to-meet-growing-sme-demand-302762228.html

Continue Reading

Technology

Frost & Sullivan Recognizes Picus Security as the 2026 Global Company of the Year for Advancing Automated Security Validation

Published

on

By

Recognition highlights Picus for pioneering a unified, AI-driven approach that is reshaping the security validation market and delivering meaningful customer impact

SAN ANTONIO, May 5, 2026 /PRNewswire/ — Frost & Sullivan today announced that it has awarded Picus Security the 2026 Global Company of the Year recognition in the automated security validation industry. This recognition highlights Picus Security’s consistent leadership in delivering measurable security outcomes, advancing innovation, and driving customer impact in a rapidly evolving threat landscape.

Each year, Frost & Sullivan presents the Company of the Year recognition to an organization that demonstrates outstanding strategy development and implementation. The firm evaluates companies based on a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Picus Security excelled in both, aligning its long-term vision with enterprise security needs while executing efficiently at scale. The company’s strategic agility and sustained investment in autonomous exposure validation have enabled it to scale effectively across North America, Asia-Pacific, and other global markets, serving large enterprises across sectors such as BFSI, healthcare, government, and technology.

“Picus Security’s rapid growth, diversified revenue streams, expanding global presence, and strong partner ecosystem reflect a company entering a new phase of accelerated scale. Its platform breadth, enterprise adoption, and continued investments across integrations, alliances, marketplaces, and service providers position it to play a pivotal role in advancing the automated security validation market,” said Ying Ting Neoh, an industry analyst at Frost & Sullivan.

Picus Security continues to differentiate through a unified, AI-driven security validation platform that integrates breach and attack simulation, automated pentesting, and autonomous exposure validation to measure real exploitability, correlate siloed findings, and reveal the small fraction of exposures that truly matter. With evidence-based reporting, compensating control guidance, and always-up-to-date attack content, Picus Security transforms enterprise security validation into a continuous, automated, and intelligence-driven practice.

“We’ve entered the Post-Mythos and GPT-Cyber era. Frontier AI models can now write exploits and launch autonomous attacks against thousands of targets in parallel, yet most enterprises are still validating their defenses at human speed,” said Volkan Ertürk, co-founder and CTO of Picus Security. “That gap is no longer survivable with periodic pentesting or manual red teaming. It demands autonomous validation: continuous, AI-driven proof that your controls hold and your real exploitable paths are closed. Frost & Sullivan’s recognition affirms that Picus is leading this shift, and that the market is ready for it.”

Frost & Sullivan commends Picus Security for setting a high standard in competitive strategy, execution, and market responsiveness. The company’s vision, innovation pipeline, and customer-first approach are shaping the future of the automated security validation industry and enabling enterprises to manage cyber risk in dynamic environments proactively.

Learn more about Picus Security’s innovation at https://www.picussecurity.com/resource/blog/why-frost-sullivan-named-picus-2026-global-company-of-the-year

Frost & Sullivan Best Practices Recognition
Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.

Contact us: Start the discussion.

About Picus Security
Picus Security, the leading security validation company, gives organizations a clear picture of their cyber risk based on business context. Picus transforms security practices by correlating, prioritizing and validating exposures across siloed findings so teams can focus on critical gaps and high-impact fixes. With Picus, security teams can quickly take action with one-click mitigations to stop more threats with less effort. Offering Adversarial Exposure Validation with Breach and Attack Simulation and Automated Penetration Testing, working together for greater outcomes, Picus delivers award-winning, threat-centric technology that allows teams to pinpoint fixes worth pursuing.

Follow Picus Security on X and LinkedIn.

Frost & Sullivan Media Contact:
Tarini Singh
E: Tarini.Singh@frost.com

Media Contact
Jennifer Tanner
Look Left Marketing
picus@lookleftmarketing.com

View original content:https://www.prnewswire.com/news-releases/frost–sullivan-recognizes-picus-security-as-the-2026-global-company-of-the-year-for-advancing-automated-security-validation-302761249.html

SOURCE Frost & Sullivan

Continue Reading

Trending